European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry

This study has been completed.
Sponsor:
Collaborator:
Foundation for Medical Research in Krakow, Poland
Information provided by:
Jagiellonian University
ClinicalTrials.gov Identifier:
NCT00378391
First received: September 19, 2006
Last updated: June 19, 2007
Last verified: June 2007
  Purpose

EUROTRANSFER Registry is a prospective, international, web-based European Registry on Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab.

This registry is designed to collect data on approximately 1800 patients during a 12 month enrollment period in up to 20 interventional cardiology centres with hospital transfer networks from all over Europe.

Analysis of this registry should allow to monitor transfer timelines of patients arriving to the cath-lab from the regional hospital with or without upstream start of abciximab and scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across Europe in regard to the impact that time of various stages of the treatment chain may have on clinical outcomes.


Condition
ST-Elevation Myocardial Infarction
Acute Coronary Syndrome

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional
Official Title: European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab

Resource links provided by NLM:


Further study details as provided by Jagiellonian University:

Estimated Enrollment: 1800
Study Start Date: November 2005
Estimated Study Completion Date: February 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

PATIENTS:

  • All consecutive STEMI patients >=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.

    • Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:

      1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or
      2. after being picked–up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.

        CENTRES:

    • Provide 24 hour/7 days on duty PCI service.
    • Has an established regional hospital referral network with >=8 patients/month arriving from transfer (as defined above).
    • A rate of >=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab.

Exclusion Criteria:

  • Patients who arrive to the Cath Lab from other pathways than those specified above (a. and b.), e.g. those who come by ambulances that do not provide specific medical therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not be included in this registry.
  • Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00378391

Locations
Finland
Helsinki University Central Hospital
Helsinki, Finland
Germany
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen, Germany
Italy
San Donato Hospital
Arezzo, Italy
Ospedale Carlo Poma
Mantova, Italy
Ospedale G.Pasquinucci
Massa, Italy
Santa Maria Nuova Hospital Reggio Emilia
Reggio Emilia, Italy
Ospedale S.Maria di Ca Foncello
Treviso, Italy
Poland
Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital
Krakow, Poland, 31-501
Department of Interventional Cardiology, John Paul II Hospital
Krakow, Poland
Szpital Wojewodzki w Przemyslu
Przemysl, Poland
Szpital im. Szczeklika Tarnow
Tarnow, Poland
Slovenia
University Medical Center Ljubljana
Ljubljana, Slovenia
Spain
Hospital Juan Canalejo
Coruna, Spain
Hospital Clinico Universitario
Santiago de Compostela, Spain
Sweden
Linköping University Hospital
Linköping, Sweden
Sponsors and Collaborators
Jagiellonian University
Foundation for Medical Research in Krakow, Poland
Investigators
Principal Investigator: Dariusz Dudek, Assoc. Prof. Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Study Chair: Zbigniew Siudak, MD Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Study Director: Lukasz Partyka, MD, PhD Krakow Cardiovascular Research Institute
  More Information

Additional Information:
No publications provided by Jagiellonian University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00378391     History of Changes
Other Study ID Numbers: H4S-PL-O067
Study First Received: September 19, 2006
Last Updated: June 19, 2007
Health Authority: Poland: Ministry of Health

Keywords provided by Jagiellonian University:
ST-Elevation Myocardial Infarction
upstream abciximab
guideline adherence
hospital networking

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Acute Coronary Syndrome
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Angina Pectoris
Chest Pain
Pain
Signs and Symptoms
Abciximab
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014